Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Free Cash Flow history
Currency unavailable · from the cash flow
No Free Cash Flow data reported for this period type.
Free Cash Flow vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M USD | -3.0% | +21.4% | — |
| LTM Mar 2026 | $164.26M USD | +92.8% | +71.8% | — | |
| LTM Mar 2026 | $127.3M USD | +121.8% | — | 58.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $80.71M USD | +16.8% | +192.3% | 403.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.66M USD | +45.8% | +40.0% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $51.71M USD | — | +134.7% | — |
| LTM Mar 2026 | $46.51M USD | +12.6% | +18.5% | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +31.3% | +55.9% | 231.0% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.